Skip to content

H2020HORIZON

Miltenyi Biotec BV & Co KG

Country
DEGermany
Defence projects
0
Projects, all programmes
26
As coordinator
1
EU contribution (CORDIS)
EUR 6,713,306
Active
2016 to 2025

Projects

26 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
T-RAFICTraining network for tracking and controlling therapeutic immune cells in cancerHORIZON2025ParticipantEUR 260,539
spaXioSpatial Crosstalk in Immuno-OncologyHORIZON2025Associated partnerNot stated
LifeLUNGImproving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapyHORIZON2025ParticipantNot stated
NANO4TALENTPost-doctoral talent attraction programme to boost research career in the field of nanomaterials for biomedicineHORIZON2025Associated partnerEUR 0
ERDERAEUROPEAN RARE DISEASES RESEARCH ALLIANCEHORIZON2024Associated partnerEUR 0
CarrerasLeadersCarreras Postdoc Program Empowering Future Leaders to Fight Blood CancersHORIZON2023Associated partnerEUR 0
FANTOMFuture of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistanceHORIZON2023Associated partnerEUR 0
ARTiDeAutoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe)HORIZON2023ParticipantEUR 1,518,750
GLIORESOLVETraining the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironmentHORIZON2022Associated partnerEUR 0
T-FITNESSFINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORSHORIZON2022ParticipantEUR 754,050
GetRadiGene Therapy of Rare DiseasesHORIZON2022ParticipantEUR 260,539
FAIR CHARMFast Infrared Coherent Harmonic MicroscopyH20202022ParticipantEUR 792,408
REAPRevealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacoustic tomographyH20202021ParticipantEUR 657,004
T2EVOLVEAccelerating Development and Improving Access to CAR and TCR-engineered T cell therapyH20202021ParticipantEUR 277,500
T-OPTraining Network for Optimizing Adoptive T cell Therapy of CancerH20202021ParticipantEUR 252,788
HUGODECAHuman Gonad Developmental Cell AtlasH20202020ParticipantEUR 242,812
INsTRuCTINnovative Training in Myeloid Regulatory Cell TherapyH20202020ParticipantEUR 277,365
NSC-ReconstructNovel Strategies for Cell-based Neural ReconstructionH20202020ParticipantEUR 323,125
ZENITHZEbrafish Neuroscience Interdisciplinary Training HubH20202019PartnerEUR 0
ENDONANOQuantitative detection of bacterial endotoxin by novel nanotechnological approachesH20202019ParticipantEUR 287,898

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.